Oncology CRO Oncotherapeutics Selects Erika Pelzer as New Director of Clinical Operations in Los Angeles, California

Online, April 19, 2012 (Newswire.com) - CEO of Oncotherapeutics, James R. Berenson, MD states, "Ms. Pelzer has a proven track record of success with major research institutes, and her operations and project management skill set and background have already made and will continue to make tremendous contributions to the ongoing success of Oncotherapeutics. We look forward to a continued partnership as she leads our Operations efforts."

Erika started her research career as a research and laboratory lead on behavioral and neuroanatomical studies. She then moved to Las Vegas, NV to assist the Arthritis and Osteoporosis Center where she developed several outreach projects specific to clinical trials. Transferring to Seattle, she was a Clinical Research Manager with UW Medicine where she honed her clinical trial operations and project management skills. Prior to joining Oncotherapeutics, Ms. Pelzer worked as a Research Project Manager for Group Health Research Institute and freelanced as a grant writer. She joined Oncotherapeutics in August of 2011 as Associate Director, Clinical Operations. In her new role, she replaces Ori Yellin, MD.

With team expertise in phase I-IV clinical trials and pharmacokinetic studies, Oncotherapeutics offers a wide array of services that are custom tailored to each trial. Nationally recognized research oncologists and key opinion leaders in the oncology field oversee senior level clinical research teams for every clinical trial. Oncotherapeutics has successfully conducted a multitude of oncology studies in the areas of multiple myeloma, myelodysplastic syndrome, monoclonal gammopathy of undetermined significance (MGUS), melanoma, non-small cell lung cancer (NSCLC), advanced melanoma, breakthrough cancer pain, other hematologic malignancies, and metastatic bone disease. For more information, please visit www.oncotherapeutics.com or call 310-623-1200.